WNT7A Regulation by miR-15b in Ovarian Cancer

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• WNT signaling pathways are crucial for development and cell functions, but their regulation is not fully understood.
• Aberrant WNT7A expression is observed in serous ovarian carcinomas, driving tumor progression via CTNNB1/TCF signaling.
• The precise regulatory mechanisms controlling WNT7A in ovarian cancer remain largely unelucidated.

Purpose of the Study:

• To investigate the post-transcriptional regulation of WNT7A by microRNAs in ovarian cancer.
• To determine the role of miR-15b in controlling WNT7A expression and its impact on ovarian cancer progression.
• To explore the potential epigenetic mechanisms regulating miR-15b expression in ovarian cancer.

Main Methods:

• Luciferase reporter assays to validate direct binding of miR-15b to the WNT7A 3'-UTR.
• Assessment of miR-15b's effect on WNT7A expression and CTNNB1/TCF signaling activity.
• Analysis of WNT7A and miR-15b expression in TCGA datasets to evaluate prognostic significance.
• Investigating the impact of decitabine treatment and DNMT1 silencing on miR-15b levels.

Main Results:

• miR-15b directly represses WNT7A expression by binding to its 3'-UTR, confirmed by luciferase assays.
• miR-15b inhibits WNT7A-induced TOPFLASH activity, indicating functional regulation of the WNT pathway.
• High WNT7A and low miR-15b expression are significantly associated with reduced survival rates in ovarian cancer patients.
• Decitabine treatment and DNMT1 silencing increase miR-15b expression, suggesting epigenetic regulation.

Conclusions:

• WNT7A is a direct post-transcriptional target of miR-15b in ovarian cancer.
• Dysregulation of the miR-15b/WNT7A axis contributes to poor prognosis in ovarian cancer.
• miR-15b may be epigenetically silenced via promoter hypermethylation, potentially involving DNMT1, offering therapeutic avenues.